Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
KYNTRA BIO, INC. entered into Financing Agreement with investment funds managed by Morgan Stanley Tactical Value valued at $75,000,000 initial term loan, $37,500,000 delayed draw term loan (effective 2023-04-29).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- investment funds managed by Morgan Stanley Tactical Value
- Value
- $75,000,000 initial term loan, $37,500,000 delayed draw term loan
- Effective
- 2023-04-29
Exact text from the filing
On April 29, 2023 (the “ Signing Date ”), FibroGen, Inc. (the “ Company ”) entered into a financing agreement (“ Financing Agreement ”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “ Lenders ”), and Wilmington Trust, National Association, as the administrative agent (the “ Administrative Agent ”), providing for senior secured term loan facilities consisting of (i) a $75,000,000 initial term loan (the “ Initial Term Loan ”), (ii) a $37,500,000 delayed draw term loan that will be funded upon the achievement of certain clinical development milestones (“ Delayed Draw Term Loan 1 ”) and, (iii) an uncommitted delayed draw term loan of up to $37,500,000, to be funded at the Lenders sole discretion, (“ Delayed Draw Term Loan 2 ” and, together with the Initial Term Loan and Delayed Draw Term Loan 1, the “ Term Loans ”).
View on SEC.gov